Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경태 | - |
dc.date.accessioned | 2018-03-13T04:20:46Z | - |
dc.date.available | 2018-03-13T04:20:46Z | - |
dc.date.issued | 2013-06 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86(2), p.304-310 | en_US |
dc.identifier.issn | 0360-3016 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0360301613001612 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/45853 | - |
dc.description.abstract | Purpose: To evaluate the efficacy and toxicity of concurrent chemoradiation with paclitaxel and carboplatin in patients with high-risk cervical cancer.Methods and Materials: Patients after radical hysterectomy for cervical cancer, with at least 1 high-risk characteristic, were administered paclitaxel 135 mg/m(2), carboplatin area under the curve = 5 every 3 weeks for 3 cycles concomitant with radiation therapy as adjuvant treatment.Results: This prospective study enrolled 71 consecutive patients. Sixty-six patients (93%) completed the planned treatment. The majority of grade 3/4 neutropenia or nonhematologic toxicities were usually self-limited. Diarrhea grades 3/4 were observed in 4 patients (5.6%). One patient developed anaphylactic shock after infusion of paclitaxel. With a median follow-up of 57 months, recurrences occurred in 16 patients. Multivariable analysis indicated that common iliac lymph node involvement is an independent risk factor for disease recurrence (odds ratio 13.48; 95% confidence interval 2.93-62.03). In the intent-to-treat population (n=71), the estimated 5-year diseasefree survival and overall survival rates were 77.3% and 80.3% respectively. In the per-protocol population (n=62), disease-free survival was 78.9% and overall survival was 83.9%.Conclusions: Concurrent chemoradiation with paclitaxel/carboplatin is well tolerated and seems to be effective for patients who undergo radical hysterectomy. Therefore, a prospective, randomized controlled study should be designed to evaluate efficacy of this approach for patients with high-risk cervical cancer. (C) 2013 Elsevier Inc. | en_US |
dc.description.sponsorship | The research was supported by grant 04-2010-0650 from the Seoul National University Hospital Research Fund. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science B.V., Amsterdam. | en_US |
dc.subject | UTERINE CERVIX | en_US |
dc.subject | CONCURRENT CHEMOTHERAPY | en_US |
dc.subject | RADIATION-THERAPY | en_US |
dc.subject | PELVIC RADIATION | en_US |
dc.subject | CLINICAL-TRIAL | en_US |
dc.subject | STAGE IB | en_US |
dc.subject | RADIOTHERAPY | en_US |
dc.subject | CARCINOMA | en_US |
dc.subject | CISPLATIN | en_US |
dc.subject | EFFICACY | en_US |
dc.title | Chemoradiation With Paclitaxel and Carboplatin in High-Risk Cervical Cancer Patients After Radical Hysterectomy: A Korean Gynecologic Oncology Group Study | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 86 | - |
dc.identifier.doi | 10.1016/j.ijrobp.2013.01.035 | - |
dc.relation.page | 304-310 | - |
dc.relation.journal | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | - |
dc.contributor.googleauthor | Lee, Taek Sang | - |
dc.contributor.googleauthor | Kang, Soon Beom | - |
dc.contributor.googleauthor | Kim, Young Tak | - |
dc.contributor.googleauthor | Park, Byung Joo | - |
dc.contributor.googleauthor | Kim, Yong Man | - |
dc.contributor.googleauthor | Lee, Jong Min | - |
dc.contributor.googleauthor | Kim, Seok Mo | - |
dc.contributor.googleauthor | Kim, Young Tae | - |
dc.contributor.googleauthor | Kim, Jae Hoon | - |
dc.contributor.googleauthor | Kim, Kyung Tai | - |
dc.relation.code | 2013010379 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | kimkt | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.